Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
This research aims to evaluate whether participants who have previously taken donanemab experience clinical benefits when receiving annual doses. The study focuses on individuals with Alzheimer disease, dementia, and amyloid plaque conditions, investigating the effects of continued treatment over a period of up to 2.5 years with six visits. The trial is sponsored by Eli Lilly and Company and is conducted as a randomized, double-blind, phase 3 clinical trial. Participants are assigned to receive either donanemab or a placebo, both administered intravenously. The study follows a parallel design where each participant receives one of the two treatments. The annual dosing schedule spans up to 2.5 years, with visits planned throughout this period to monitor participants. This includes assessments of cognitive function, brain amyloid plaque levels via PET scans, plasma biomarkers, and drug concentration measurements. During the study, participants will undergo evaluations including the Clinical Dementia Rating - Sum of Boxes CDR-SB, Cognitive Function Index CFI, Florbetapir F 18 PET scans, and plasma phosphorylated tau measurements. Pharmacokinetics of donanemab will be assessed at baseline, week 52, and week 104. The study involves six visits over the entire duration, with safety and clinical benefit monitored carefully. Participation lasts up to 2.5 years, allowing comprehensive observation of treatment effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR448851, an oral medication taken once daily, in people with early Alzheimers disease, including mild cognitive impairment due to Alzheimers and mild Alzheimers dementia. This Phase 2 randomized, placebo-controlled study focuses on participants aged 55 to 85 years who have evidence of cerebral amyloid pathology. The study aims to measure changes in plasma biomarkers and monitor safety outcomes over time. Participants are randomly assigned to receive either SAR448851 at one of two doses or a placebo, taken orally once daily for 48 weeks during Part A. Those who complete Part A can join an open-label extension in Part B. The total study duration may last up to 111 weeks for Parts A and B, or up to 63 weeks for the optional dose 2 cohort. Various assessments, including brain imaging and fluid biomarker measurements, will be used to evaluate treatment effects. Throughout the trial, participants will have regular evaluations including brain MRIs to monitor for adverse events such as ARIA-E and ARIA-H, laboratory tests, vital sign checks, ECGs, and cognitive assessments. Researchers will track changes in Alzheimers disease biomarkers from baseline through Week 96. Safety and tolerability will be continuously assessed, and participants cognitive status will be monitored to understand the treatments impact over time.
Actively Recruiting
Researchers are studying familial hypercholesterolemia and related lipid disorders to improve treatment and reduce cardiovascular risks. The study aims to enhance lipid disorder management by partnering with primary care providers and using electronic health records to identify high-risk patients. The goal is to develop a prevention model that integrates treatment guidelines at the practice level, focusing on lowering LDL cholesterol levels in affected individuals. Participants with high LDL-C levels, especially those with familial hypercholesterolemia or related conditions, will receive supportive care through a comprehensive outreach approach. This includes database screening, secure communication with healthcare providers, genetic testing encouragement, education, medication adherence support, routine lab testing, specialist referrals, and follow-up visits either in person or virtually. Additional consultations with pharmacists, nutritionists, genetic counselors, or specialists may be provided to manage coexisting conditions. During the study, patients LDL-C levels will be monitored, with the primary measure being the proportion maintaining LDL-C below 100 mgdL six months after enrollment. Secondary outcomes include achieving LDL-C levels below 75 and 55 mgdL. The study involves ongoing medical management, routine lab tests, and access to integrated care resources, aiming to improve lipid control and reduce cardiovascular risks over time.
Actively Recruiting
Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.